Apolipoprotein E4 (apoE4) is the strongest genetic risk factor for Alzheimer's disease. Despite nearly 25 years of research, the mechanism by which apoE4 confers increased risk for Alzheimer's disease remains enigmatic. In this issue of Neuron, Liu et al. (2017) and Huynh et al. (2017) shed new light on this important question.
Alzheimer's disease (AD) is the most common dementia of the elderly (Masters et al., 2015) . There are currently more than 5 million AD patients in the US, and this number may increase to 16 million by the mid-21 st century. No diseasemodifying therapy exists for this devastating neurodegenerative disorder, and if one is not developed, then an epidemic of AD will ensue as the population ages in the coming decades. Age is the primary risk factor for AD, yet very little is known about physiological processes of aging that predispose to AD. Human genetic studies have provided insight into the pathogenesis of AD with the discovery of rare, early-onset autosomal dominant forms of AD (ADAD) that are caused by mutations in the genes for amyloid precursor protein (APP) and the presenilins (PSEN1, PSEN2). ADAD mutations increase the production of 42 aa amyloid-b (Ab), a proteolytic fragment of APP that accumulates in extracellular amyloid plaques, a hallmark lesion of AD brain. These observations have led to the amyloid hypothesis of AD, positing that the aggregation and accumulation of cerebral Ab initiates a cascade of pathophysiological changes that eventually lead to neurodegeneration and dementia (Selkoe and Hardy, 2016) . A vast number of molecular, cellular, animal model, and human studies performed over the past three decades strongly supports the amyloid hypothesis, yet approaches based on its elements have so far failed to yield therapies, underscoring the need for further research.
Although the ADAD mutations have been enormously insightful for understanding AD pathogenesis, they are exceedingly rare in the AD population and therefore cannot explain the vast majority of sporadic late-onset AD cases. This situation changed dramatically with the discovery in 1993 that the ε4 allele of the APOE gene encoding apolipoprotein E (apoE4) was the strongest genetic risk factor for AD (Strittmatter et al., 1993) . Over 50% of sporadic AD is associated with apoE4. The APOE gene has three alleles-ε2, ε3, and ε4-that differ by only two single-nucleotide polymorphisms in the coding region of the gene, and individuals that carry one or two copies of the ε4 allele have 3.7-or 12-fold increased risk of developing AD, respectively, relative to individuals with the ε3/ε3 genotype (Roses, 1994) . Moreover, the ε4 allele confers an earlier age of disease onset in a gene dose-dependent fashion compared to that of ε3 (Farrer et al., 1997) . Over two decades of research has provided insight into the role of apoE4 in AD. A leading hypothesis is that apoE4 affects the aggregation and clearance of Ab, yet the mechanisms involved and whether they can be exploited for the development of AD therapies are poorly understood. Now, the reports by Liu et al. (2017) and Huynh et al. (2017) in this issue of Neuron shed new light on both of these old questions.
An important unanswered question regarding the role of apoE4 in Ab aggregation is whether apoE4 affects the initial slow seeding stage of Ab deposition or influences the rapid growth stage of plaque development. To address this question, Liu et al. (2017) undertook a series of intriguing experiments by making innovative conditional knockin mice in which human apoE3 or apoE4 isoforms are expressed from astrocytes, the major apoE-generating cell type in the CNS, in a temporally controlled fashion by doxycycline treatment. The team first showed that, in their knockin mice, apoE3 or apoE4 is strictly expressed only in astrocytes by 3-fold over endogenous mouse apoE and that doxycycline treatment for 2 weeks tightly shuts off human apoE expression. To determine the role of apoE isoforms during Ab seeding and plaque growth, Liu et al. (2017) crossed their apoE knockins with APP SWE /PS1DE9 transgenic mice that start depositing Ab at 4-5 months postnatally and exhibit rapid plaque growth between 6 and 9 months of age (referred to as APP/iE3 or APP/iE4 mice). They then compared three groups of mice with different apoE expression profiles starting from birth: (1) apoE on continuously until 9 months of age (0-9 m on: both Ab seeding and rapid plaque growth stages); (2) apoE on until 6 months of age, then off for 3 months (0-6 m on: Ab seeding stage only); and (3) apoE off until 6 months of age, then on for 3 months (6-9 m on: rapid plaque growth stage only). Importantly, 0-9 m on and 0-6 m on APP/iE4 mice exhibited dramatic increases in Ab deposition during the seeding stage, but 6-9 m on APP/iE4 mice showed no difference with control when apoE was expressed during the plaque growth stage. In contrast to APP/iE4 mice, 0-9 m on and 0-6 m on APP/iE3 mice showed no evidence of an apoE-induced increase in Ab deposition. Thus, apoE4 appeared to have the greatest impact on the Ab seeding stage but had little, if any, effect on the plaque growth stage. Interestingly, 0-9 m on and 0-6 m on APP/iE4 mice had markedly more plaqueassociated dystrophic neurites, AD pathologic hallmarks caused by fibrillar Ab, while 6-9 m on APP/iE4 and 0-9 m on APP/iE3 mice showed no such changes. Next, the team used in vivo microdialysis to measure Ab levels in the cerebral interstitial fluid and determined that the Ab half-life was approximately doubled in APP/iE4 mice compared to littermate control mice, indicating that apoE4 impairs the clearance of Ab in the brain. Finally, Liu et al. (2017) determined that APP/iE3 mice had reduced gliosis and increased levels of the post-synaptic protein PSD95, while APP/iE4 mice displayed elevated astrogliosis and microgliosis, demonstrating opposing effects of the two apoE isoforms on neuroinflammation.
In the second study, Huynh et al. (2017) used a different molecular genetic approach, that of antisense oligonucleotides (ASOs), to investigate the effects of lowering apoE before and after the onset of Ab deposition. By intracerebroventricular (ICV) injection of ASOs directed against apoE mRNA, Huynh et al. (2017) was able to reduce apoE levels by more than 50% in the brains of knockin mice in which the endogenous mouse Apoe gene was replaced by either the ε3 or the ε4 allele of the human APOE gene. Notably, the ASOs even reduced apoE in the adult after only a 2-week treatment period, demonstrating the effectiveness of this experimental approach in the mature brain. To explore the effect of apoE reduction on amyloid pathology, they then crossed their apoE knockin mice with APP/PS1-21 transgenic mice, an aggressive amyloid pathology model that develops Ab deposits at 2 months of age, to generate compound transgenics that were homozygous for either ε3 (APP/PS1-21/ε3) or ε4 (APP/PS1-21/ε4). Mice were injected ICV with ASOs at postnatal day 0 (P0) or 6 weeks of age, given a mid-treatment ASO booster injection, and finally analyzed at 16 weeks for apoE expression, histological and biochemical assessment of Ab deposition, and microgliosis. Huynh et al. (2017) found that ASO treatment at P0 (encompassing the Ab seeding stage) decreased the area of Ab-immunolabeled and X-34 amyloid dye-stained Ab deposits by 50%, lowered Ab levels by ELISA, and significantly reduced the amount of dystrophic neurites that surround amyloid plaques. ASO treatment had a more potent effect on APP/PS1-21/ε4 compared to APP/PS1-21/ε3 mice, indicating that apoE4 has a stronger impact on the early stages of Ab aggregation than apoE3. Next, the team showed that ASO treatment at 6 weeks (encompassing the plaque growth stage), the age of earliest detectable plaque formation in this model, had little effect on total amyloid load, although dystrophic neurites around plaques were reduced by almost 50%. Interestingly, the size of Ab-immunostained deposits was increased in the mice treated at the beginning of plaque formation, even though the X-34 stained fibrillar plaque core size was unchanged. Huynh et al. (2017) did not observe global changes in microgliosis in any treatment group, although they leave the possibility open for local apoEdependent alterations in microglial responses to plaques. Thus, similar to Liu et al. (2017) , the results of Huynh et al. (2017) suggest a critical role for apoE during the initial seeding of Ab deposits, with apoE4 driving seed formation more strongly than apoE3. However, once plaque seeds have nucleated, apoE has little influence on total amyloid load but instead affects plaque size and neuritic dystrophy.
The results of Liu et al. (2017) and Huynh et al. (2017) have critical importance for understanding the mechanistic role of apoE4 in AD pathogenesis, a question that has remained enigmatic for nearly 25 years. Strikingly, the two studies arrive at identical conclusions by using different molecular genetic approaches to move apoE levels in opposite directions-increased inducible gene-driven apoE expression (Liu et al., 2017) and decreased ASO treatment-driven apoE expression (Huynh et al., 2017) . Thus, the concordance of results obtained by these different approaches strongly supports the role of apoE in Ab seed formation rather than plaque growth. Additionally, both studies agree that apoE4 more potently promotes Ab seeding than apoE3. This latter finding nicely explains the ε4 allele dose-dependent reduction of AD age of onset.
Consisting of distended axons and dendrites filled with vesicles, autophagic intermediates, mitochondria, and other organelles, dystrophic neurites are major AD lesions thought to contribute to pathophysiology and dysfunction in AD brain (Dickson, 1997 ). An interesting finding of both studies is that the formation of dystrophic neurites is significantly affected by apoE4, the mechanism of which is unclear. The results suggest that apoE4 intensifies the toxicity of the amyloid plaque toward axons and dendrites in contact with the deposit. An intriguing observation of Huynh et al. (2017) was that ASO treatment of APP/ PS1-21/ε4 at 6 weeks increased plaque size and frequency as shown by Ab immunostaining, although X-34 dye staining that labels the b sheet fibrillar core of the plaque showed no such increase. Since overall amyloid load was unchanged, these results imply that the increased ASO-associated plaque size and frequency derived from deposition of nonfibrillar, and thus perhaps less toxic, Ab. Understanding how apoE4 alters Ab toxicity is an important goal of future studies.
Finally, the therapeutic implications of these studies are profound, namely that apoE-targeted therapies, in particular for APOE4 carriers, need to be administered very early in the disease process to affect Ab-related pathogenic mechanisms, preferably for prevention before the occurrence of significant Ab seeding. This strategy may reduce the risk of failure for future AD clinical trials, provided lowamyloid presymptomatic patient populations most likely to benefit from an apoEtargeted therapy are recruited. Their findings also highlight potential benefits of segregating patients into different treatment groups according to their APOE genotype status. Of note, a recent study shows that apoE also influences tau-mediated neurodegeneration (Shi et al., 2017) . If this bears out, one might be able to still target apoE somewhat later in the process of AD pathogenesis and still have beneficial effects of apoE lowering. Increasing the success of AD clinical trials is a critical goal given the poor AD trial track record of the past decade (Cummings, 2017) . The combined results of Liu et al. (2017) and Huynh et al. (2017) provide deep mechanistic insights into how APOE4 is the strongest genetic risk factor for AD and add very crucial voices to the growing chorus of early intervention for prevention of AD.
